Early Stage Commercialization Affinity Therapeutics is a pre-revenue, technology licensing and commercialization venture focused on controlled release platforms for therapeutics. This creates a sales opportunity targeting strategic partnerships with medical device firms, wound care companies, and hernia mesh manufacturers seeking novel delivery mechanisms.

Platform Opportunity The core platform enables release rates and durations beyond diffusion limits, suggesting potential upsell through licensing deals, co-development agreements, or branded collaborations with established biotech, device, and pharmaceutical players looking to differentiate their products.

Focused Markets Target markets include advanced wound care and hernia mesh sectors, where controlled release can improve outcomes and reduce complications. Sales efforts should prioritize partnerships with device manufacturers and healthcare providers focused on these segments.

Lean Funding With capital of $550K and revenue under $1M, there is room for grant support, non-dilutive funding, and milestone-driven partnerships. Opportunities exist to approach early-stage investors, government programs, and strategic partners to accelerate product validation.

Evidence and Visibility Affiliation with Case Western Reserve University tech base and a modern tech stack (cloud, open-source, and analytics tools) can be leveraged in pitches to demonstrate credibility, regulatory readiness, and scalable digital infrastructure to prospective partners.